News

ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.

Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.

Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.

ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.

All three major US stock indexes were up in late-morning trading Monday, after Iran's Ministry of Fo

Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.

On this episode of Stock Movers with Alexis Christoforous: - Shares of The Campbell's Company (CPB) edged higher ahead of the US market open after the canned soup maker reported adjusted earnings per share for the third quarter that beat the average analyst estimate. - Eli Lilly (LLY) shares gained in the early session following obesity drug presentations at the American Diabetes Association conference. Citi analysts say their conviction on Lilly is firmly intact, given the company's incretin portfolio is "not built around singular blockbusters." - Shares of Marvell Technology (MRVL) and Flex (FLEX) are rising in premarket trading as the companies are set to replace Pool Corp. and Campbell's in S&P 500 before the market open on June 22, S&P Dow Jones Indices says in emailed statement.

Popping onto the IBD Leaderboard and two exclusive screens, Eli Lilly stock has returned to buy range after a brief hiccup.

Health care's seasonal strength and defensive appeal are in focus, with Eli Lilly's growth and Merck's pipeline progress highlighted as key drivers.

NVO says real-world data show Ozempic 2 mg matches Eli Lilly's Mounjaro on glucose control and is linked to a higher likelihood of meaningful weight loss.

NVO's oral Wegovy launch is off to a blistering start, topping 3 million prescriptions in five months and drawing many first-time GLP-1 users.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4%, and the actively tra

Eli Lilly (LLY) shares were up more than 2% pre-bell Monday after the company reported Saturday addi

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

The drugmaker's recent outperformance is a sideshow to its more valuable, long-term trait for investors.

US equity futures were edging higher pre-bell Monday as President Donald Trump tried to hold togethe

Foundayo Data Could Broaden Lilly's Obesity Market Opportunity

Participants on the highest dose of retatrutide lost an average of 28.3% of their body weight over 80 weeks, Lilly said

The benchmark US stock measures were mostly pointing higher before the opening bell Monday as invest

Eli Lilly (LLY) shares rose early Monday after the drugmaker said its experimental obesity drug reta

The brutal AI selloff that rocked the market on Friday may end up being short-lived, judging by how chip makers were trading early Monday.

Eli Lilly and Company (NYSE:LLY) shares gained 4. 5% after the pharmaceutical giant unveiled additional clinical data on its obesity treatment retatrutide during the American Diabetes Association (ADA) conference over the weekend.

Eli Lilly reported promising data for Retatrutide and Foundayo at the American Diabetes Association (ADA) 86th Scientific Sessions over the weekend.

Eli Lilly (NYSE:LLY) reported Phase 3 results for obesity drugs retatrutide and Foundayo at the American Diabetes Association 86th Scientific Sessions in 2026. The data show strong weight loss outcomes and benefits in related conditions such as sleep apnea, knee osteoarthritis pain, and type 2 diabetes. The trials include at-risk groups, including women at different life stages and patients with multiple metabolic conditions. Eli Lilly is already widely followed for its work in diabetes and...

The weight-loss rivals provided positive updates on their obesity treatments but to differing reactions among investors.

A late-stage trial showed retatrutide was effective in weight loss and in alleviating obesity-linked conditions.

Retail sentiment remained constructive. Stocktwits data showed traders continued to maintain a ‘bullish’ stance on SPY and ‘neutral’ on QQQ.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at branded pharmaceuticals stocks, starting with Eli Lilly (NYSE:LLY).

Solidion Technology, Eli Lilly, and Citigroup clocked fresh yearly highs amid breakthrough technology announcements, clinical data expectations, and broader market optimism.

Veru (VERU) stock has not been easy to own. The little biotech has spent years persuading investors that its experimental obesity technique can matter in a market dominated by giants. That's a tough sell with Novo Nordisk (NVO) and Eli Lilly (LLY) already owning the narrative with blockbuster ...